Cargando…

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt

Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the African meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A (MenA). It is important to consider how best to sustain population protection i...

Descripción completa

Detalles Bibliográficos
Autores principales: Karachaliou, Andromachi, Conlan, Andrew J. K., Preziosi, Marie-Pierre, Trotter, Caroline L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639487/
https://www.ncbi.nlm.nih.gov/pubmed/26553693
http://dx.doi.org/10.1093/cid/civ508
_version_ 1782399921208426496
author Karachaliou, Andromachi
Conlan, Andrew J. K.
Preziosi, Marie-Pierre
Trotter, Caroline L.
author_facet Karachaliou, Andromachi
Conlan, Andrew J. K.
Preziosi, Marie-Pierre
Trotter, Caroline L.
author_sort Karachaliou, Andromachi
collection PubMed
description Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the African meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A (MenA). It is important to consider how best to sustain population protection in the long term. Methods. We created a mathematical model of MenA transmission and disease to investigate the potential impact of a range of immunization strategies. The model is age structured; includes classes of susceptible, carrier, ill, and immune people (who may be vaccinated or unvaccinated); and incorporates seasonal transmission and a stochastic forcing term that models between year variation in rates of transmission. Model parameters were primarily derived from African sources. The model can describe the typical annual incidence of meningitis in the prevaccine era, with irregular epidemics of varying size. Parameter and structural uncertainty were explored in sensitivity analyses. Results. Following MenAfriVac introduction at high uptake, the model predicts excellent short-term disease control. With no subsequent immunization, strong resurgences in disease incidence were predicted after approximately 15 years (assuming 10 years’ average vaccine protection). Routine immunization at 9 months of age resulted in lower average annual incidence than regular mass campaigns of 1- to 4-year-olds, provided coverage was above approximately 60%. The strategy with the lowest overall average annual incidence and longest time to resurgence was achieved using a combination strategy of introduction into the Expanded Programme on Immunization at 9 months, 5 years after the initial mass campaigns, with a catch-up targeting unvaccinated 1- to 4-year-olds. Conclusions. These results can be used to inform policy recommendations for long-term vaccination strategies with MenAfriVac.
format Online
Article
Text
id pubmed-4639487
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-46394872015-11-12 Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt Karachaliou, Andromachi Conlan, Andrew J. K. Preziosi, Marie-Pierre Trotter, Caroline L. Clin Infect Dis The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Background. The introduction of MenAfriVac in campaigns targeting people aged 1–29 years across the African meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A (MenA). It is important to consider how best to sustain population protection in the long term. Methods. We created a mathematical model of MenA transmission and disease to investigate the potential impact of a range of immunization strategies. The model is age structured; includes classes of susceptible, carrier, ill, and immune people (who may be vaccinated or unvaccinated); and incorporates seasonal transmission and a stochastic forcing term that models between year variation in rates of transmission. Model parameters were primarily derived from African sources. The model can describe the typical annual incidence of meningitis in the prevaccine era, with irregular epidemics of varying size. Parameter and structural uncertainty were explored in sensitivity analyses. Results. Following MenAfriVac introduction at high uptake, the model predicts excellent short-term disease control. With no subsequent immunization, strong resurgences in disease incidence were predicted after approximately 15 years (assuming 10 years’ average vaccine protection). Routine immunization at 9 months of age resulted in lower average annual incidence than regular mass campaigns of 1- to 4-year-olds, provided coverage was above approximately 60%. The strategy with the lowest overall average annual incidence and longest time to resurgence was achieved using a combination strategy of introduction into the Expanded Programme on Immunization at 9 months, 5 years after the initial mass campaigns, with a catch-up targeting unvaccinated 1- to 4-year-olds. Conclusions. These results can be used to inform policy recommendations for long-term vaccination strategies with MenAfriVac. Oxford University Press 2015-11-15 2015-11-09 /pmc/articles/PMC4639487/ /pubmed/26553693 http://dx.doi.org/10.1093/cid/civ508 Text en © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Karachaliou, Andromachi
Conlan, Andrew J. K.
Preziosi, Marie-Pierre
Trotter, Caroline L.
Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
title Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
title_full Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
title_fullStr Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
title_full_unstemmed Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
title_short Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
title_sort modeling long-term vaccination strategies with menafrivac in the african meningitis belt
topic The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639487/
https://www.ncbi.nlm.nih.gov/pubmed/26553693
http://dx.doi.org/10.1093/cid/civ508
work_keys_str_mv AT karachaliouandromachi modelinglongtermvaccinationstrategieswithmenafrivacintheafricanmeningitisbelt
AT conlanandrewjk modelinglongtermvaccinationstrategieswithmenafrivacintheafricanmeningitisbelt
AT preziosimariepierre modelinglongtermvaccinationstrategieswithmenafrivacintheafricanmeningitisbelt
AT trottercarolinel modelinglongtermvaccinationstrategieswithmenafrivacintheafricanmeningitisbelt